PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fluprednidene→

Fluprednidene PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2193-87-5
Molecular formula
C22H27FO5
Molecular weight
390.4 g/mol
Drug class
Topical glucocorticoid corticosteroidanti-inflammatory dermatological agent
Mechanism of action
Activates intracellular glucocorticoid receptors and suppresses inflammatory mediator production and immune-cell activity in skin, reducing erythema, oedema and pruritus.
Indications / reported uses
  • Fluprednidene acetate is used in fixed topical combinations with an antifungal such as miconazole for inflammatory skin disease accompanied by fungal infection, according to the specific product authorisation. This entry does not establish a stand-alone fluprednidene indication.

Sources: https://targetpharma.gr/wp-content/uploads/2017/07/Flenazole_EN_PIL_2608201_v2_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fluprednidene PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluprednidene Permitted Daily Exposure (PDE) report (the Fluprednidene PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluprednidene Occupational Exposure Limit (OEL) report (the Fluprednidene OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.